The Latest Breaking News from Eli Lilly

Options Corner: Embattled Drug Maker Novo Nordisk May Offer Speculators A Quick Profit-Scalping Opportunity

From the doldrums of the COVID-19 crisis to the early summer of 2024, few major pharmaceutical companies enjoyed as much market success as Novo Nordisk (NYSE:NVO). Much of the success was tied into the company's weight-loss drugs Wegovy and Ozempic. However, competition in the space has intensified, particularly from Eli…

Benzinga · Aug 22, 2025

Serena Williams reveals GLP-1 treatment helped her lose 31 pounds after giving birth

After years of struggling with postpartum weight gain despite strict training and healthy eating, the 23-time Grand Slam champion turned to a GLP-1 medication.

Euronews · Aug 22, 2025

Wegovy sales spike after maker of rival Mounjaro ramps up UK price

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.

Evening Standard · Aug 22, 2025

Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

International Business Times UK · Aug 19, 2025

Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks

Insiders are buying stocks like LLY, TFX, and CALC. The question is whether they are also a good buy for investors, and not all of them are.

MarketBeat · Aug 19, 2025

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.

Benzinga · Aug 19, 2025

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

On Tuesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released the much-awaited data from its Phase 2 trial of VK2735 pill, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Benzinga · Aug 19, 2025

2 Outstanding ‘Strong Buy’ Stocks to Grab in August

These two stocks offer a rare combination of income and growth.

Barchart · Aug 19, 2025

Ozempic price slashed following Donald Trump's demands - will it impact the UK cost?

Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump

Evening Standard · Aug 19, 2025

Weight loss drugs: how will you be affected by the Mounjaro price rise in the UK?

We’d like to hear from people who are taking Mounjaro and how they feel about the increase in cost for doses

The Guardian - UK · Aug 19, 2025